HCV / Hepatitis

Yasaswi Kislovskiy, MD, MSc, specialized in reproductive infectious disease to advocate for gender equity in health care.

Experts are advocating for occult hepatitis B to be spotlighted.

Occult HBV infection is likely to go undetected in under-resourced regions of high HBV endemicity and confound WHO goal to eradicate the viral hepatitis by 2030.

With an all-ready challenging patient population to treat, having a program to get more people into treatment can be helpful in an underserved group.

Among pregnant women coinfected with HIV, a higher hepatitis C viral load increased the likelihood of transmitting HCV to children.

However, according to one study the risk of heart inflammation increases with age and amplifies in patients with hepatitis C (HCV) compared to patients without HCV.

A meta-analysis study shows having the comorbidity presents significant health risks for this patient population.

Adenovirus was determined to have caused most cases of hepatitis of unknown origin in children.

The same 5-year survival rates with kidney transplants from HCV positive and negative donors supports revising HCV "penalty" in ranking donors.

WHO and CDC have laid out some ambitious goals for the treatment of hepatitis C, and HCV co-discoverer and vaccine developer Michael Houghton, PhD, offers some insights and commentary on whether he feels it is realistic to consider the eradication of this stubborn and subtle virus.

The Liver Health Initiative’s Thelma King Thiel, and HCV co-discoverer and vaccine developer Michael Houghton, PhD, are a “Dynamic Duo” that are working together to bring about an end to this virus.

Nobel Prize Laureate Michael Houghton, PhD, discusses the arduous journey to find the virus and a subsequent investigational vaccine designed to prevent hepatitis C (HCV).

Injection drug users who received accessible care treatment at a syringe service program were almost 3 times as likely to complete their hepatitis C treatment than people who received usual care.

Catch up on all the important news and clinical care topics you may have missed this week.

Reviewers weigh evidence for the benefit of oral PrEP protection from HIV with risk of exacerbating hepatitis B.

A new report underscores a persistent problem of patients not receiving antivirals despite their high curative rate.

A biotech company is utilizing this platform to rid people of the virus using a technology that differs from CRISPR-Cas9.

Rates of hepatitis C reinfection were low among people receiving opioid agonist therapy, according to a new study, which highlights the importance of risk reduction interventions and HCV treatment for people who inject drugs and people receiving opioid agonist therapy.

WHO guidelines on HIV, hepatitis and STIs focus on populations with high risk of infections but low inclusion in prevention and treatment programs.

WHO issues new HCV treatment recommendations that include "radical simplification" of care pathways, in pursuit of testing and treatment goals.

At AIDS 2022, Gilead presented data suggesting Biktarvy was a safe and effective complete HIV treatment regimen, including for those coinfected with hepatitis B.

Implicating adenovirus for hepatitis of unknown cause in children is confounded by its absence in some cases, and from all tested hepatic tissue.

Viral hepatitis “can and should be managed within primary care,” says Dr. Thomas Robertson.

The FDA and other health agencies are investigating fresh organic strawberries, branded as FreshKampo or HEB, that are believed to be the source of hepatitis A infections in the US and Canada.

A shorter dosing period and no extra risk of suffering acute myocardial infarction means the newer 2-dose hepatitis B vaccine is an attractive option for protection.

The cases are in the pediatric population and come from 11 countries in the WHO European Region and 1 country in the WHO Region of the Americas.

The federal agency's new guidelines for adults between 19-59 years replaces risk-based recommendations.

Incidence of hepatitis B has fallen in the Asia and Pacific region, but progress against hepatitis C in the region has lagged and morbidity and mortality continued to rise, underscoring a need to improve diagnosis and linkage of care, according to a recent report.

The CDC’s Advisory Committee on Immunization Practices voted to recommend hepatitis B, orthopoxviruses, and Ebola vaccines to certain populations, as well as approving 2022 immunization schedules for children, adolescents, and adults.

HIV coinfection was associated with a 3.7-fold increase in the risk of non-liver-related cancer among patients with hepatitis C virus infection, a new study found.